

Manual of Federal Practice, 4th Ed.
 Bankruptcy Law & Practice, 6th Ed.
 Bankruptcy (Epstein, Nickels & White)
 Corbin on Contracts
 Insurance Law (Appleman)
 Search & Seizure (Thomson)
 Ballantine's Law Dictionary
 California ADR Practice Guide
 California Civil Practice Handbook:
 Choice Between State and Federal
 Courts
 California Civil Trialbook
 California Litigation By the Numbers
 Court Rules Companion
 California Negligence & Settlement
 California Products Liability Law &
 Practice
 California Digest
 California Trial
 California Tort Law
 Modern California Discovery
 Colorado Trial Handbook
 Trial Handbook for Connecticut
 Lawyers
 Florida Criminal Practice & Procedure
 Florida Evidence 2d
 Illinois Jurisprudence
 Indiana Appellate Handbook 2d
 Kentucky Probate PSL
 Kentucky Workers' Compensation PSL
 Louisiana Code of Evidence—Annotated
 Louisiana Successions
 Louisiana Workers' Compensation
 Massachusetts Corporations PSL
 Massachusetts Domestic Relations PSL
 Massachusetts Landlord-Tenant Law
 Massachusetts Real Estate PSL
 Michigan Criminal Law
 Michigan Digest
 Michigan Law & Practice
 New Jersey Criminal Procedure
 New York Wills and Trusts
 New York Estate Administration
 Ohio Family Law
 Ohio Probate
 Pennsylvania Law Encyclopedia
 Modern Texas Discovery
 Texas Civil Pre-Trial Procedure
 Texas Trial and Appellate Practice
 Washington Trial Handbook
 Wisconsin Digest

Exhibit C

Definition of HHI and Calculations for Nine Markets

"HHI" means the Herfindahl-Hirschman Index, a commonly accepted measure of market concentration. It is calculated by squaring the market share of each firm competing in the market and then summing the resulting numbers. For example, for a market consisting of four firms with shares of thirty, thirty, twenty, and twenty percent, the HHI is 2600 ($30^2+30^2+20^2+20^2=2600$). The HHI takes into account the relative size and distribution of the firms in a market and

approaches zero when a market consists of a large number of firms of relatively equal size. The HHI increases both as the number of firms in the market decreases and as the disparity in size between those firms increases.

Markets in which HHI is between 1000 and 1800 are considered to be moderately concentrated, and those in which the HHI is in excess of 1800 points are considered to be concentrated. Transactions that increase the HHI by more than 100 points in concentrated markets presumptively raise antitrust concerns under the Merger Guidelines. See *Merger Guidelines* § 1.51.

The HHIs for the nine primary law markets are as follows:

	Post merger	HHI increase
The market for:		
Enhanced United States Supreme Court case law	5023	959
Enhanced United States statutory law	9019	3964
Enhanced California statutory law	8088	3866
Enhanced California case law	4762	1540
Enhanced New York statutory law	8686	3792
Enhanced Massachusetts statutory law	8954	4234
Enhanced Michigan statutory law	8702	4196
Enhanced Washington case law	4521	996
Enhanced Wisconsin case law	5535	2424

Certificate of Service

I, Keith S. Blair, hereby certify that on June 25, 1996, I caused a copy of the Competitive Impact Statement, filed this day in *United States v. The Thomson Corporation and West Publishing Company*, to be served on defendants the Thomson Corporation and West Publishing Company by having a copy mailed, first class, postage prepaid, to:

Wayne D. Collins, Esq., Shearman & Sterling, Citicorp Building, 153 East 53rd Street, New York, New York 10022, Counsel for The Thomson Corporation.

James E. Schatz, Esq., Schatz Paquin Lockridge Grindal & Holstein P.L.L.P., Suite 2200, 100 Washington Avenue So., Minneapolis, MN 55401, Counsel for West Publishing Company.

Dated: June 25, 1996,

Keith S. Blair.

[FR Doc. 96-16891 Filed 7-3-96; 8:45 am]

BILLING CODE 4410-01-M

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 13, 1996, Dupont Pharmaceuticals, The Dupont Merck Pharmaceutical Company, 1000 Stewart Avenue, Garden City, New York 11530, made application to the Drug Enforcement Administration (DEA) for registration as bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Oxycodone (9143)	II
Hydrocodone (9193)	II
Oxymorphone (9652)	II

The firm plans to manufacture the listed controlled substances to make finished products.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than September 3, 1996.

Dated: June 27, 1996.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 96-17063 Filed 7-3-96; 8:45 am]

BILLING CODE 4410-09-M

Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with § 1311.42 of Title 21, Code of Federal Regulations (CFR), notice is hereby